Nursing Diagnoses for Chlamydia: Comprehensive STD Care Guide

Introduction

Chlamydia, caused by the bacterium Chlamydia trachomatis, is a prevalent sexually transmitted infection (STI) and the most reported bacterial infection in the United States. Globally, it remains a leading cause of STIs. Beyond genital infections, C. trachomatis is responsible for trachoma, an eye infection that is the primary infectious cause of blindness worldwide. In women, chlamydia infections can lead to severe complications such as infertility and ectopic pregnancies, posing significant healthcare challenges and costs.¹ Lymphogranuloma venereum (LGV), a less common condition caused by specific Chlamydia trachomatis serovars, manifests as enlarged lymph nodes or proctocolitis.² Nurses play a vital role in managing patients with chlamydia, and accurate nursing diagnoses are crucial for effective care planning and patient outcomes in sexually transmitted diseases. This article will focus on nursing diagnoses relevant to chlamydia infections, providing a comprehensive guide for healthcare professionals.

Common Nursing Diagnoses for Chlamydia

Identifying appropriate nursing diagnoses is the foundation for providing patient-centered care for individuals with chlamydia. These diagnoses address the multifaceted needs of patients affected by this STI. Common nursing diagnoses include:

• Impaired Tissue Integrity: Related to the inflammatory process of chlamydia infection affecting various anatomical sites.
• Deficient Knowledge: Regarding chlamydia infection, its transmission, treatment, and prevention.
• Anxiety: Associated with the diagnosis of a sexually transmitted infection and its potential implications for health and relationships.
• Ineffective Protection: Linked to compromised body defenses against infection and potential reinfection.
• Sexual Dysfunction: May arise due to symptoms of infection, psychological impact of STI diagnosis, or complications of chlamydia.
• Acute Pain: Associated with inflammatory processes in the reproductive organs, urethra, or rectum.
• Situational Low Self-Esteem: Related to the stigma associated with STIs and the impact on self-perception.
• Risk for Infection Transmission: Potential for spreading the infection to sexual partners if not properly managed.

Etiology of Chlamydia Infections

Chlamydia trachomatis belongs to the Chlamydophila genus, characterized as gram-negative, anaerobic, obligate intracellular bacteria that replicate within eukaryotic cells. This bacterium is categorized into 18 serovars, each associated with different clinical manifestations.³ Understanding these serovars is important for comprehending the diverse presentations of chlamydial infections:

• Serovars A, B, Ba, and C: Primarily responsible for trachoma, a severe eye disease endemic in regions of Africa and Asia. Chronic conjunctivitis caused by these serovars can lead to blindness if untreated.
• Serovars D-K: These serovars are the main culprits behind genital tract infections, including cervicitis in women and urethritis in men, and are the focus when considering nursing diagnoses for STDs in a general context.
• Serovars L1-L3: Cause lymphogranuloma venereum (LGV), a condition more prevalent in tropical countries and characterized by genital ulcer disease and lymph node involvement.

Risk Factors for Chlamydia

Chlamydia is a widespread STI, particularly among young adults. Several factors increase the risk of acquiring a urogenital chlamydia infection. It’s crucial for nurses to assess these risk factors to identify individuals who would benefit from screening and education.

Urogenital chlamydia infections are most frequently reported among young people. Women in the U.S. are diagnosed with urogenital infections at twice the rate of men, with the highest prevalence in women aged 15-24. Men experience a higher incidence between 20-24 years of age. This age distribution highlights the importance of targeted screening and prevention efforts in these age groups.

Assessment Findings in Chlamydia

C. trachomatis infections can manifest in various anatomical locations, leading to a range of clinical syndromes. Nurses must be adept at recognizing the signs and symptoms of chlamydia to facilitate timely diagnosis and intervention.

Chlamydia can cause urogenital infections including cervicitis, pelvic inflammatory disease (PID), urethritis, epididymitis, prostatitis, and lymphogranuloma venereum. Extragenital infections include conjunctivitis, perihepatitis (Fitz-Hugh-Curtis syndrome), pharyngitis, reactive arthritis, and proctitis.

A significant challenge in chlamydia management is that most individuals are asymptomatic carriers, acting as reservoirs for transmission. When symptoms do occur, they vary depending on the infection site. Key signs and symptoms of C. trachomatis urogenital infections that nurses should be aware of include:

• Pelvic Inflammatory Disease (PID): Occurs when chlamydia ascends to the upper reproductive tract in women. Patients typically present with abdominal or pelvic pain, often accompanied by signs and symptoms of cervicitis.
• Urethritis: More common in men, urethritis presents with dysuria (painful urination) and urethral discharge. The discharge is often white, gray, or clear and may only be noticeable after penile stripping or in the morning. Differentiating clinically between gonococcal and chlamydial urethritis is unreliable without laboratory testing.
• Epididymitis: Men with epididymitis typically experience unilateral testicular pain and tenderness, possible hydrocele, palpable epididymal swelling, and fever.
• Proctitis: Patients with chlamydial proctitis report rectal pain, discharge, and bleeding, particularly in individuals engaging in receptive anal intercourse.
• Lymphogranuloma venereum (LGV): LGV initially presents as a small, painless genital ulcer, followed by inguinal lymphadenopathy (swollen lymph nodes in the groin).

Diagnostic Evaluation for Chlamydia

Diagnosis of chlamydia, except for trachoma, relies on laboratory confirmation. Nursing interventions often begin after a positive diagnosis, but understanding the diagnostic process is crucial for patient education and care coordination.

While trachoma may be diagnosed clinically based on eye examination findings in endemic areas, other chlamydial infections require laboratory confirmation. Nucleic acid amplification testing (NAAT) is the gold standard for diagnosing urogenital chlamydia infections. NAAT can be performed on vaginal swabs in women or first-catch urine in men. Endocervical or urethral swabs are also suitable specimens. Alternative diagnostic methods include culture, rapid antigen tests, serology, antigen detection, and genetic probes. In resource-limited settings where testing is unavailable, treatment decisions may be based on clinical presentation and risk assessment.

Medical Management of Chlamydia

Medical treatment aims to eradicate the infection, prevent complications, reduce transmission risk, and alleviate symptoms. Nurses play a key role in ensuring patients understand and adhere to the prescribed medical regimen.

Azithromycin is the preferred first-line treatment for uncomplicated urogenital chlamydia infection due to its single-dose administration, which enhances adherence. Doxycycline is an alternative, but requires a multi-day course.

Co-infection with chlamydia and gonorrhea is common. In men, co-treatment for gonorrhea is guided by NAAT or Gram stain detection of Neisseria gonorrhoeae. In women, Gram stain is less reliable due to normal vaginal flora, and co-treatment decisions are based on individual risk assessment and local gonorrhea prevalence.

Patient management includes partner notification, testing, and treatment. Patients should be counseled on safe sex practices, advised to abstain from sexual activity for one week after starting treatment, and offered HIV testing.

Test of cure is recommended three weeks post-treatment, and retesting should be done at three months to detect reinfection, which is common. Persistent symptoms post-treatment warrant investigation for co-infections or reinfection.

Nursing Management for Chlamydia: Addressing Nursing Diagnoses

Nursing care for patients with chlamydia is comprehensive and addresses the various nursing diagnoses identified. Effective nursing management is essential for positive patient outcomes and public health.

• Educating Patients about Chlamydia Infections (Deficient Knowledge): Provide thorough education on chlamydia, including its causes, transmission, symptoms, complications, treatment, and prevention. Tailor education to the patient’s understanding level and address their specific concerns.
• Promoting Safe Sex Practices (Risk for Infection Transmission, Ineffective Protection): Emphasize the importance of consistent and correct condom use to prevent chlamydia and other STIs. Discuss risk reduction strategies, partner notification, and the importance of regular STI screening, especially for those at higher risk.
• Encouraging Medication Compliance (Ineffective Management of Therapeutic Regimen): Reinforce the importance of completing the full course of prescribed antibiotics, even if symptoms resolve. Explain potential consequences of non-compliance, such as treatment failure and development of antibiotic resistance. For azithromycin, emphasize the importance of the single dose treatment. For doxycycline, provide clear instructions on dosage and duration and manage potential side effects.
• Monitoring Laboratory Results (Impaired Tissue Integrity, Risk for Infection Transmission): Review culture and NAAT results to confirm diagnosis and guide treatment. Monitor repeat testing results to ensure treatment effectiveness and detect reinfection. For women of childbearing age, confirm pregnancy status before prescribing doxycycline, as it is contraindicated in pregnancy.
• Administering Antibiotics as Ordered (Impaired Tissue Integrity, Acute Pain): Administer prescribed antibiotics according to established protocols. Provide information about potential side effects and how to manage them.
• Facilitating Partner Notification (Risk for Infection Transmission, Deficient Knowledge): Encourage patients to notify their sexual partners about their chlamydia diagnosis so partners can be tested and treated. Explain the rationale for partner notification in preventing further transmission and reinfection. Provide information about expedited partner therapy (EPT) if available and appropriate.
• Ensuring Follow-up Care (Risk for Infection Transmission, Ineffective Protection): Emphasize the importance of follow-up appointments for test of cure and repeat STI screening. Provide referrals to STD clinics or other healthcare providers as needed.

Coordination of Care for Chlamydia

Effective chlamydia management requires a coordinated approach involving clinicians, nurses, pharmacists, and public health agencies. Screening programs are pivotal in controlling chlamydia prevalence.

In developed countries, screening recommendations target sexually active non-pregnant women aged 25 and younger annually. Pregnant women should be screened, and women over 25 with risk factors (new or multiple partners) should also be screened. Screening young men in high-risk settings (STD clinics, correctional facilities) is also recommended when resources allow. Urine or endocervical NAAT are the recommended screening tests. Early treatment leads to an excellent prognosis, with antibiotic therapy being 95% effective for initial infections.

Currently, no vaccine is available for chlamydia. The healthcare team must collaborate to educate patients on prevention methods and the importance of treatment adherence. Public health initiatives focused on screening, partner services, and health education are crucial for reducing the burden of chlamydia infections.

Health Teaching and Health Promotion for Chlamydia

Given the high prevalence of asymptomatic chlamydia infections and the potential for serious sequelae if untreated, health education and promotion are paramount nursing responsibilities.

Screening recommendations are based on the silent nature of chlamydia and its potential complications. All pregnant women should be screened. Sexually active females under 25 should be screened annually. Women over 25 with STI risk factors (multiple partners, new partners, inconsistent condom use, history of STI, exchanging sex for money/drugs) should be screened. Men who have sex with men should also be screened. Individuals with HIV should be screened at initial presentation and annually. Screening is recommended for women 35 and younger and men 30 and younger entering correctional facilities.

C. trachomatis is a reportable infection in the United States. Nurses should be aware of local and state reporting laws. Patient education should include the importance of partner notification and treatment. Expedited partner therapy (EPT), where allowed, can facilitate partner treatment and reduce reinfection rates.

Emphasize to patients the serious consequences of untreated chlamydia and the benefits of screening. Educate that screening can often be done non-invasively with urine samples, which may increase patient willingness to be tested. Empowering patients with knowledge about chlamydia and screening is key to promoting sexual health and preventing complications.

Review Questions

What are the common nursing diagnoses associated with chlamydia infection?

What are the primary risk factors for chlamydia infection?

Describe the recommended medical management for uncomplicated chlamydia.

Outline key nursing interventions for a patient diagnosed with chlamydia, focusing on addressing nursing diagnoses.

Figure

Electron Microscopic View of Chlamydia Bacteria: A Visual Aid for Nursing Education on STDs. Chlamydial bodies are indicated by arrows; note the destruction of interstitial connective tissue. This image highlights the cellular impact of chlamydia, relevant for understanding tissue integrity impairment in nursing diagnoses.

Figure

Follicular Conjunctivitis in Chlamydia Infection: Understanding Ocular Manifestations for Nursing Assessment. This image illustrates conjunctivitis, an extragenital manifestation of chlamydia. Follicular inflammation, as shown, can be associated with chlamydial infections, highlighting the importance of assessing for ocular symptoms in patients at risk for STDs.

References

1.Owusu-Edusei K, Chesson HW, Gift TL, Tao G, Mahajan R, Ocfemia MC, Kent CK. The estimated direct medical cost of selected sexually transmitted infections in the United States, 2008. Sex Transm Dis. 2013 Mar;40(3):197-201. PubMed: 23403600

2.Mabey D, Peeling RW. Lymphogranuloma venereum. Sex Transm Infect. 2002 Apr;78(2):90-2. PMC free article: PMC1744436 PubMed: 12081191

3.Morré SA, Rozendaal L, van Valkengoed IG, Boeke AJ, van Voorst Vader PC, Schirm J, de Blok S, van Den Hoek JA, van Doornum GJ, Meijer CJ, van Den Brule AJ. Urogenital Chlamydia trachomatis serovars in men and women with a symptomatic or asymptomatic infection: an association with clinical manifestations? J Clin Microbiol. 2000 Jun;38(6):2292-6. PMC free article: PMC86784 PubMed: 10834991

4.Mordhorst CH, Dawson C. Sequelae of neonatal inclusion conjunctivitis and associated disease in parents. Am J Ophthalmol. 1971 Apr;71(4):861-7. PubMed: 4928532

5.Detels R, Green AM, Klausner JD, Katzenstein D, Gaydos C, Handsfield H, Pequegnat W, Mayer K, Hartwell TD, Quinn TC. The incidence and correlates of symptomatic and asymptomatic Chlamydia trachomatis and Neisseria gonorrhoeae infections in selected populations in five countries. Sex Transm Dis. 2011 Jun;38(6):503-9. PMC free article: PMC3408314 PubMed: 22256336

6.Pelvic inflammatory disease. Am Fam Physician. 2012 Apr 15;85(8):797-8. PubMed: 22534389

7.Kobayashi S, Kida I. Reactive arthritis: recent advances and clinical manifestations. Intern Med. 2005 May;44(5):408-12. PubMed: 15942084

8.Schachter J, Grossman M, Sweet RL, Holt J, Jordan C, Bishop E. Prospective study of perinatal transmission of Chlamydia trachomatis. JAMA. 1986 Jun 27;255(24):3374-7. PubMed: 3712696

9.Tipple MA, Beem MO, Saxon EM. Clinical characteristics of the afebrile pneumonia associated with Chlamydia trachomatis infection in infants less than 6 months of age. Pediatrics. 1979 Feb;63(2):192-7. PubMed: 440806

10.Kohlhoff SA, Hammerschlag MR. Treatment of Chlamydial infections: 2014 update. Expert Opin Pharmacother. 2015 Feb;16(2):205-12. PubMed: 25579069

11.Workowski KA, Bolan GA., Centers for Disease Control and Prevention. Sexually transmitted diseases treatment guidelines, 2015. MMWR Recomm Rep. 2015 Jun 05;64(RR-03):1-137. PMC free article: PMC5885289 PubMed: 26042815

12.Stamm WE, Batteiger BE, McCormack WM, Totten PA, Sternlicht A, Kivel NM., Rifalazil Study Group. A randomized, double-blind study comparing single-dose rifalazil with single-dose azithromycin for the empirical treatment of nongonococcal urethritis in men. Sex Transm Dis. 2007 Aug;34(8):545-52. PubMed: 17297383

13.Rours GI, Duijts L, Moll HA, Arends LR, de Groot R, Jaddoe VW, Hofman A, Steegers EA, Mackenbach JP, Ott A, Willemse HF, van der Zwaan EA, Verkooijen RP, Verbrugh HA. Chlamydia trachomatis infection during pregnancy associated with preterm delivery: a population-based prospective cohort study. Eur J Epidemiol. 2011 Jun;26(6):493-502. PMC free article: PMC3115062 PubMed: 21538042

Disclosures: Michael Mohseni declares no relevant financial relationships with ineligible companies. Sharon Sung declares no relevant financial relationships with ineligible companies. Veronica Takov declares no relevant financial relationships with ineligible companies. Chaddie Doerr declares no relevant financial relationships with ineligible companies.